Linked Life Data

16510744

Source:http://linkedlifedata.com/resource/pubmed/id/16510744

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2006-3-2
pubmed:databankReference
pubmed:abstractText
Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1533-4406
pubmed:author
pubmed:copyrightInfo
Copyright 2006 Massachusetts Medical Society.
pubmed:issnType
Electronic
pubmed:day
2
pubmed:volume
354
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
899-910
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:16510744-Adolescent, pubmed-meshheading:16510744-Adult, pubmed-meshheading:16510744-Antibodies, Monoclonal, pubmed-meshheading:16510744-Antibodies, Monoclonal, Humanized, pubmed-meshheading:16510744-Brain, pubmed-meshheading:16510744-Cell Adhesion Molecules, pubmed-meshheading:16510744-Disease Progression, pubmed-meshheading:16510744-Drug Hypersensitivity, pubmed-meshheading:16510744-Fatigue, pubmed-meshheading:16510744-Female, pubmed-meshheading:16510744-Humans, pubmed-meshheading:16510744-Infusions, Intravenous, pubmed-meshheading:16510744-Integrin alpha4, pubmed-meshheading:16510744-Magnetic Resonance Imaging, pubmed-meshheading:16510744-Male, pubmed-meshheading:16510744-Middle Aged, pubmed-meshheading:16510744-Multiple Sclerosis, Relapsing-Remitting, pubmed-meshheading:16510744-Proportional Hazards Models, pubmed-meshheading:16510744-Recurrence
pubmed:year
2006
pubmed:articleTitle
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
pubmed:affiliation
Vrije Universiteit Medical Center, Amsterdam, The Netherlands. ch.polman@vumc.nl
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III